Literature DB >> 25256711

A functional screen identifies miRs that induce radioresistance in glioblastomas.

Patryk Moskwa1, Pascal O Zinn2, Young Eun Choi3, Sachet A Shukla4, Wojciech Fendler5, Clark C Chen6, Jun Lu7, Todd R Golub8, Anita Hjelmeland9, Dipanjan Chowdhury10.   

Abstract

UNLABELLED: The efficacy of radiotherapy in many tumor types is limited by normal tissue toxicity and by intrinsic or acquired radioresistance. Therefore, it is essential to understand the molecular network responsible for regulating radiosensitivity/resistance. Here, an unbiased functional screen identified four microRNAs (miR1, miR125a, miR150, and miR425) that induce radioresistance. Considering the clinical importance of radiotherapy for patients with glioblastoma, the impact of these miRNAs on glioblastoma radioresistance was investigated. Overexpression of miR1, miR125a, miR150, and/or miR425 in glioblastoma promotes radioresistance through upregulation of the cell-cycle checkpoint response. Conversely, antagonizing with antagomiRs sensitizes glioblastoma cells to irradiation, suggesting their potential as targets for inhibiting therapeutic resistance. Analysis of glioblastoma datasets from The Cancer Genome Atlas (TCGA) revealed that these miRNAs are expressed in glioblastoma patient specimens and correlate with TGFβ signaling. Finally, it is demonstrated that expression of miR1 and miR125a can be induced by TGFβ and antagonized by a TGFβ receptor inhibitor. Together, these results identify and characterize a new role for miR425, miR1, miR125, and miR150 in promoting radioresistance in glioblastomas and provide insight into the therapeutic application of TGFβ inhibitors in radiotherapy. IMPLICATIONS: Systematic identification of miRs that cause radioresistance in gliomas is important for uncovering predictive markers for radiotherapy or targets for overcoming radioresistance. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25256711      PMCID: PMC4386891          DOI: 10.1158/1541-7786.MCR-14-0268

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells.

Authors:  Yi Chieh Lim; Tara L Roberts; Bryan W Day; Angus Harding; Sergei Kozlov; Amanda W Kijas; Kathleen S Ensbey; David G Walker; Martin F Lavin
Journal:  Mol Cancer Ther       Date:  2012-07-06       Impact factor: 6.261

2.  miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes.

Authors:  Harsh Dweep; Carsten Sticht; Priyanka Pandey; Norbert Gretz
Journal:  J Biomed Inform       Date:  2011-05-14       Impact factor: 6.317

Review 3.  MicroRNAs and DNA damage response: implications for cancer therapy.

Authors:  Yemin Wang; Toshi Taniguchi
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

4.  Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms.

Authors:  Shangqin Guo; Haitao Bai; Cynthia M Megyola; Stephanie Halene; Diane S Krause; David T Scadden; Jun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

Review 5.  Charity begins at home: non-coding RNA functions in DNA repair.

Authors:  Dipanjan Chowdhury; Young Eun Choi; Marie Eve Brault
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-06       Impact factor: 94.444

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1.

Authors:  Xiaoyong Huang; Samira Taeb; Sahar Jahangiri; Urban Emmenegger; Elisa Tran; Jeff Bruce; Aruz Mesci; Elina Korpela; Danny Vesprini; C Shun Wong; Robert G Bristow; Fei-Fei Liu; Stanley K Liu
Journal:  Cancer Res       Date:  2013-10-21       Impact factor: 12.701

8.  Rapid generation of microRNA sponges for microRNA inhibition.

Authors:  Joost Kluiver; Johan H Gibcus; Chris Hettinga; Annelies Adema; Mareike K S Richter; Nancy Halsema; Izabella Slezak-Prochazka; Ye Ding; Bart-Jan Kroesen; Anke van den Berg
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

9.  MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma.

Authors:  M Shiiba; K Shinozuka; K Saito; K Fushimi; A Kasamatsu; K Ogawara; K Uzawa; H Ito; Y Takiguchi; H Tanzawa
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

10.  MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines.

Authors:  S Grosso; J Doyen; S K Parks; T Bertero; A Paye; B Cardinaud; P Gounon; S Lacas-Gervais; A Noël; J Pouysségur; P Barbry; N M Mazure; B Mari
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

View more
  11 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

Review 2.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

3.  There and Back Again: The Middle Earth of DNA Repair.

Authors:  Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2016-10       Impact factor: 5.852

4.  Functional Screen for microRNAs Suppressing Anchorage-Independent Growth in Human Cervical Cancer Cells.

Authors:  Angelina Huseinovic; Annelieke Jaspers; Annina P van Splunter; Hanne Sørgård; Saskia M Wilting; Dorian R A Swarts; Ida H van der Meulen; Victor W van Beusechem; Renée X de Menezes; Renske D M Steenbergen
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

5.  Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid.

Authors:  Johnny C Akers; Valya Ramakrishnan; Isaac Yang; Wei Hua; Ying Mao; Bob S Carter; Clark C Chen
Journal:  Cancer Biomark       Date:  2016-03-25       Impact factor: 4.388

Review 6.  MicroRNAs Involvement in Radioresistance of Head and Neck Cancer.

Authors:  Parwez Ahmad; Jiri Sana; Marek Slavik; Pavel Slampa; Pavel Smilek; Ondrej Slaby
Journal:  Dis Markers       Date:  2017-02-23       Impact factor: 3.434

7.  Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300.

Authors:  M Boissinot; H King; M Adams; J Higgins; G Shaw; T A Ward; L P Steele; D Tams; R Morton; E Polson; B da Silva; A Droop; J L Hayes; H Martin; P Laslo; E Morrison; D C Tomlinson; H Wurdak; J Bond; S E Lawler; S C Short
Journal:  Oncogene       Date:  2020-06-17       Impact factor: 9.867

8.  Differentially Expressed MicroRNAs in Radioresistant and Radiosensitive Atypical Meningioma: A Clinical Study in Chinese Patients.

Authors:  Xiaokang Zhang; Guobin Zhang; Huawei Huang; Haoyi Li; Song Lin; Yonggang Wang
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

9.  MiR-502 is the first reported miRNA simultaneously targeting two components of the classical non-homologous end joining (C-NHEJ) in pancreatic cell lines.

Authors:  Agnieszka Smolinska; Julia Swoboda; Wojciech Fendler; Markus M Lerch; Matthias Sendler; Patryk Moskwa
Journal:  Heliyon       Date:  2020-01-18

Review 10.  Radioresistance in Glioblastoma and the Development of Radiosensitizers.

Authors:  Md Yousuf Ali; Claudia R Oliva; Abu Shadat M Noman; Bryan G Allen; Prabhat C Goswami; Yousef Zakharia; Varun Monga; Douglas R Spitz; John M Buatti; Corinne E Griguer
Journal:  Cancers (Basel)       Date:  2020-09-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.